about
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological studyManaging therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinenceVarying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelinesPolypharmacy patterns: unravelling systematic associations between prescribed medicationsComparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological studyImproving Treatment Adherence in Heart Failure.A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?Managing blood pressure control in Asian patients: safety and efficacy of losartan.Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heartPotential New Agents for the Management of Hyperkalemia.New medications for heart failure.Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care.The appropriate dose of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews
P2860
Q26782126-57036D02-0955-4CA6-BE8D-0CB36D87621DQ27027072-18981D75-4AAD-4804-BCEE-E44CA8000D1AQ28069387-3420E37C-D18F-4647-A8FB-C39CEA0C5960Q28537875-E4BAEFDD-FFE5-447B-9723-B45FA3F7668FQ28677533-F23AEFC4-B4EF-4DC0-8591-BCEDBF78B113Q30314088-511FBFF6-AE49-46D6-9FB4-1E623DD173FEQ35139947-2224FFF3-1DCC-4DBC-883B-87B263638A23Q36661094-BFAF0265-E099-4943-9749-69868AA9EFA5Q37659693-AEFDB11E-B777-4F96-BA3E-C470D34B346AQ37695746-0ACD8B8E-BB63-4E37-9433-10A45C99EA77Q38175345-CB79486A-3FFA-49F1-806E-3D3EF3781B48Q38537344-F301236F-C65B-4709-8B95-19F8C6D87D22Q38544101-B79F5B25-469A-432D-9AB7-17510FF90654Q38546656-E9BE6716-0DB1-477E-A3A7-122530F75CD8Q38846247-3B83B990-E2B1-40E4-A746-712BB8346242Q38862008-2482D855-4AB3-4B46-B616-EAFFBBC0ED58Q42383448-8EB5450B-6A57-4431-BA1D-6FECE0EDA3BCQ57174292-08A949BC-A71E-4B7B-99E6-9C487165E08B
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Angiotensin receptor blockers for heart failure
@ast
Angiotensin receptor blockers for heart failure
@en
Angiotensin receptor blockers for heart failure
@en-gb
Angiotensin receptor blockers for heart failure
@nl
type
label
Angiotensin receptor blockers for heart failure
@ast
Angiotensin receptor blockers for heart failure
@en
Angiotensin receptor blockers for heart failure
@en-gb
Angiotensin receptor blockers for heart failure
@nl
prefLabel
Angiotensin receptor blockers for heart failure
@ast
Angiotensin receptor blockers for heart failure
@en
Angiotensin receptor blockers for heart failure
@en-gb
Angiotensin receptor blockers for heart failure
@nl
P2093
P2860
P3181
P1476
Angiotensin receptor blockers for heart failure
@en
P2093
Balraj S Heran
James M Wright
Ken Bassett
Rod S Taylor
Vijaya M Musini
P2860
P304
P3181
P356
10.1002/14651858.CD003040.PUB2
P577
2012-04-18T00:00:00Z